MedPath

Biodistribution of Tc-99m-BTG-N4 - a retrospective evaluatio

Conditions
C61
Malignant neoplasm of prostate
Registration Number
DRKS00030296
Lead Sponsor
Klinik für Nuklearmedizin, Universitätsklinikum Augsburg
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Male
Target Recruitment
5
Inclusion Criteria

Histologically confirmed prostate carcinoma and an examination with 99mTc-BTG-N4

Exclusion Criteria

None

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The aim of the retrospective analysis is to determine the biodistribution of the GRPR ligand 99mTc-BTG-N4 and in particular the radiation dose for organs and the whole body.<br>time period: 05.07.2021 - 20.07.2022<br>Method: The Volume of Interest is drawn around the corresponding organs and the activity concentration in the different acquired images is determined. Other clinical parameters and the activity values show the residence time of the radiopharmaceutical in the individual organs.<br><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath